In CML, mutation of the gatekeeper Thr315 to Ile confers drug resistance [50], suggesting that an analogous mutation in DDR1 and DDR2 would also confer resistance to imatinib. The gene discussed is DDR2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.